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The  exposome  is a complement  to  the  genome  that  includes  non-genetic  causes  of disease.  Multiple
deﬁnitions  are  available,  with  salient  points  being  global  inclusion  of  exposures  and  behaviors,  and  cumu-
lative  integration  of  associated  biologic  responses.  As  such,  the concept  is both  refreshingly  simple  and
dauntingly  complex.  This article  reviews  high-resolution  metabolomics  (HRM)  as  an  affordable  approach
to  routinely  analyze  samples  for a broad  spectrum  of  environmental  chemicals  and  biologic  responses.
HRM  has been  successfully  used  in  multiple  exposome  research  paradigms  and  is  suitable  to implement
in  a prototype  universal  exposure  surveillance  system.  Development  of  such  a structure  for  systematic
monitoring  of  environmental  exposures  is an important  step  toward  sequencing  the exposome  because  it
builds  upon  successes  of exposure  science,  naturally  connects  external  exposure  to body  burden  and  par-
titions  the  exposome  into  workable  components.  Practical  results  would  be repositories  of  quantitative
data  on  chemicals  according  to geography  and  biology.  This  would  support  new  opportunities  for  envi-
ronmental  health  analysis  and  predictive  modeling.  Complementary  approaches  to  hasten  development
of  exposome  theory  and  associated  biologic  response  networks  could  include  experimental  studies  with
model  systems,  analysis  of archival  samples  from  longitudinal  studies  with  outcome  data  and  study  of
relatively  short-lived  animals,  such  as  household  pets  (dogs  and  cats)  and  non-human  primates  (common
marmoset).  International  investment  and  cooperation  to sequence  the  human  exposome  will  advance  sci-
entiﬁc  knowledge  and  also  provide  an important  foundation  to control  adverse  environmental  exposures
to  sustain  healthy  living  spaces  and  improve  prediction  and  management  of  disease.
©  2015  The  Author.  Published  by Elsevier  Ireland  Ltd. This  is  an  open  access  article  under  the CC. Introduction and deﬁnitions
The exposome is the cumulative measure of environmental
nﬂuences and biological responses throughout the lifespan [28].
he deﬁnition is inclusive, consistent with Christopher Wild’s con-
ept [44] to broadly complement the genome with non-genetic
actors impacting human health. Measurements of all environmen-
al, dietary, microbiome, behavioral, therapeutic and endogenous
rocesses present a daunting challenge for systematic study, espe-
ially when considered cumulatively throughout life.
Less than a half-century ago, sequencing the human genome
as imaginable by few scientists. Yet visionary leaders championedhis goal, societies and industries invested in new technologies, and
uccess was attained. Despite monumental barriers, earlier gen-
rations succeeded in quests to control communicable diseases,
 This article was  presented in a session entitled “Genome, Epigenome and Expo-
ome” at the 45th Annual Symposium of the Society of Toxicology of Canada, Ottawa,
ecember 4, 2013.
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ttp://dx.doi.org/10.1016/j.toxrep.2015.11.009
214-7500/© 2015 The Author. Published by Elsevier Ireland Ltd. This is an open access a
d/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
eradicate smallpox, prevent polio, cure childhood leukemia, etc.
Sequencing the human exposome is a formidable challenge for
contemporary science and technology, but with vision and com-
mitment, this is attainable.
Wild [44] provided a thoughtful outline to address the chal-
lenge, and others have emphasized the need for critical thought and
design to pursue this goal [34,1,45]. In the present article, I provide
a brief review on environmental applications of high-resolution
metabolomics (HRM; see Table 1 for acronym deﬁnitions) and com-
ment on the potential to use this as a central framework to initiate
sequencing the human exposome. I use the term “sequencing” to
emphasize the time domain of the exposome; the cumulative mea-
sure of exposures for an individual cannot be sequenced in the same
way as the genome can be sequenced. But there are many types
of exposure memory systems [17], and there is little doubt that
improved understanding of epigenetics and other exposure mem-
ory systems will allow certain aspects of an individual’s exposome
to be measured retrospectively. So the present review of HRM is
not intended as a ﬁnal chapter on how to sequence the exposome,
but rather as a place to begin.
I  ﬁrst describe the use of high-resolution mass spectrome-
try for clinical metabolic proﬁling and discuss advantages and
rticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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imitations. This is followed by a discussion of computational work-
ows, which support both targeted and discovery analyses using
ommonly accessible biological samples and advanced informat-
cs methods. I then consider use of this analytical platform as a
niversal surveillance tool to monitor environmental exposures
nd evaluate biological effects. Finally, I discuss HRM as a possi-
le central element of a “Human Exposome Project” to sequence
he cumulative environmental inﬂuences and biological responses
hroughout lifespan. This is presented as a call to the international
nvironmental health research community to champion this effort
nd work together in this common goal. At Emory University, in
ollaboration with Georgia Institute of Technology and with sup-
ort of the National Institute of Environmental Health Sciences,
e are building toward this goal through the HERCULES Expo-
ome Research Center directed by Gary W.  Miller, Ph.D. (http://
umanexposomeproject.com).
. Rationale for development of high-resolution
etabolomics
Analytical traditions, as well as regulatory and policy needs of
overnment, have limited ﬂexibility to address important chal-
enges in health and environmental research. During the period
rom 1958, when automated amino acid analysis was  introduced
29], and 2007, when we began experimental development of
dvanced blood chemistry analyses with high-resolution mass
pectrometry [16], analytical chemistry provided merely a ten-fold
mprovement in the number of chemicals that could be measured
n a routine analysis of plasma or serum, i.e., from about 30 to
00. During this time period, DNA sequencing progressed from a
omplete inability to sequence the human genome to ability to
ccomplish the task within a few days.
While considerable ﬁnancial investment through the Human
enome Project contributed importantly to this success, practical
ifferences from analytical chemistry also existed in the scope of
he human genome initiative and in the tolerance of the project
or errors. Genome sequencing was intended to be more or less
omplete and was pursued even for genes without known func-
ion. Additionally, whole genome sequencing was  developed with
n expectation for errors in sequencing and assembly. Instead of
bandonment because methods were inadequate or errors were
ommon, progress was made by embracing new methods and
able 1
bbreviations and acronym deﬁnitions [For additional MS  details, see [30]].
Term Deﬁnition Term
AMU  Atomic mass unit m/z 
apLCMS Adaptive processing algorithms for extraction of MS  data MB  
Asp  Aspartate MS 
Cd  Cadmium MS/M
CV Coefﬁcient of variation MS1
ESI  Electrospray ionization MS2
FDR  False discovery rate MSn
FT  Fourier transform MWA
FT-ICR Type of mass analyzer PBDE
GC  Gas chromatography PD 
GC–MS Combined gas chromatography and mass spectrometry Phe 
GWAS Genome-wide association study PLS-D
HIV  Human immunodeﬁciency virus PQ 
HMDB Human metabolome database Q 
HPLC High performance liquid chromatography Q-TO
HRM  High-resolution metabolomics SOP 
ICR  Ion cyclotron resonance, a type of mass analyzer SRM1
Ile  Isoleucine TMW
KEGG Kyoto encyclopedia of genes and genomes TOF 
LC  Liquid chromatography Tyr 
LC-MS Combined liquid chromatography and mass spectrometry UHRA
Leu  Leucine XCMS
LIMMA Linear models for microarray, software for differential expression xMSaorts 3 (2016) 29–45
developing new approaches to address errors. Although imperfect
in many ways, this resulted in overall success.
In contrast, progress in analytical coverage of small molecules
in biologic systems appears to have languished more due to ana-
lytical traditions than to limitations in technology. With a focus
on matching proteomic capabilities to those of genomics, tremen-
dous advances in technology were achieved in mass spectrometry
(MS). A byproduct of the successes of proteomics was the transfor-
mation of MS  capabilities for detection and measurement of small
molecules.
2.1. Mass spectrometry for chemical proﬁling
Mass spectrometry (MS) has a special role in analytical chem-
istry because the mass of a chemical is an absolute property. Thus, if
the measured mass does not match that of the purported chemical,
then the chemical identiﬁcation is incorrect. MS  involves mea-
surement of chemicals or derived fragments of chemicals as ions
(m/z, mass-to-charge ratio) in the gas phase [13]. The ions can be
formed by interaction of a neutral chemical with H+, Na+ or other
cation, by loss of H+ as occurs with ionization of carboxylic acids,
or by dissociation of a chemical into product ions. With introduc-
tion of electrospray ionization (ESI) [47], routine measurement of a
very broad range of small molecules in biological materials without
extensive fragmentation became practical.
Mass spectrometers have three components, an ion source,
which generates ions; a mass analyzer, which separates ions
according to m/z; and a mass detector, which measures ion inten-
sity, i.e., the amount of ions with the respective m/z  (Fig 1A). Many
physical and chemical principles are used for MS instruments, and a
recent overview is available [25]. Mass spectrometers differ in sen-
sitivity to detect low abundance ions, resolve ions with very similar
m/z, and provide accurate estimates of m/z. For instruments with
poorer mass resolution and mass accuracy, chromatographic sepa-
ration prior to MS  is necessary to allow measurement of chemicals
with the same unit mass (Fig 1B). Both gas chromatography (GC)
and liquid chromatography (LC) are often coupled to MS  to improve
measurement of chemicals according to characteristic retention
time and m/z (Fig 1A and B).
Quadrupole mass analyzers, often designated simply by “Q”,
selectively stabilize or destabilize the paths of ions passing through
oscillating electrical ﬁelds between 4 parallel rods. Common
 Deﬁnition
Mass to charge ratio for an ion measured by mass spectrometry
Maneb, a fungicide
Mass spectrometry
S  First product ion spectrum from ion dissociation MS;  same as MS2
Spectrum of a precursor ion
First product ion spectrum from ion dissociation MS;  same as MS/MS
Product ion spectra from a sequence of ion dissociations
S  Metabolome-wide association study
 Polybrominated diphenyl ether,
Parkinson disease
Phenylalanine
A Partial least squares-discriminant analysis
Paraquat, an herbicide
Quadrupole, a type of mass analyzer
F Tandem mass spectrometer combining quadrupole and TOF
Standard operating procedures
950 National institute of standards pooled reference human plasma
AS  Transcriptome metabolome-wide association study
Time-Of-Flight, a type of mass analyzer
Tyrosine
M Ultra-high resolution accurate mass, used in reference to FT MS
 Algorithms for MS  data extraction
nalyzer Algorithms to improve data extraction by apLCMS or XCMS
D.P. Jones / Toxicology Reports 3 (2016) 29–45 31
Fig. 1. Mass spectrometry (MS) for metabolomics. A. Mass is a fundamental characteristic of a chemical, and mass spectrometers measure mass by converting chemicals to
ions  in the gas phase and measuring the movement of the ions in an electromagnetic ﬁeld. Mass spectrometers have an ion source to generate ions, a mass analyzer that
separates ions according to mass to charge ratio (m/z) and a detector to quantify the intensity of respective ions with corresponding m/z. For metabolomics, samples are
usually  fractionated prior to delivery to the ion source by gas chromatography (GC) or liquid chromatography (LC). B. Many mass spectrometers measure m/z with ±0.1
atomic mass unit (AMU), which is not sufﬁcient to distinguish chemicals with very similar mass. Consequently, these instruments require separation by GC,  LC or other
methods prior to mass spectral analysis. Such conﬁgurations are designated by hybrid terms: GC–MS or LC–MS. C. Tandem mass spectrometry (e.g., triple quadrupole and
Q-TOF  instruments) involves use of combinations of mass spectrometry components to obtain m/z measurements on an ion and then subsequent measurement of m/z for
product ions generated following ion dissociation. In some instruments, this process can be repeated multiple times (MSn) to gain additional structural information; for
quantiﬁcation, the ﬁrst ion dissociation (MS/MS or MS2) is often used for targeted chemical analysis because it allows quantiﬁcation of speciﬁc chemicals based upon product
i  mass
a esolut
c n plas
v
e
p
s
M
M
n
m
t
s
q
e
p
a
i
t
h
mons  even when the precursor ion is not separated from chemicals with very similar
nd  measure m/z much more precisely than other mass spectrometers. This mass r
apability to measure low abundance chemicals in complex matrices such as huma
ariations include tandem mass spectrometers where sequential
lements allow selection and dissociation of precursor ions into
roduct ions. Simpliﬁed terminology for ion dissociation mass
pectrometry is to refer to the spectrum of the precursor ion as
S or MS1, the spectrum of the products of ion dissociation as
S/MS  or MS2, and subsequent dissociation spectra as MSn, where
 represents the corresponding fragmentation sequence. Tandem
ass spectrometers include triple quadrupole mass spectrome-
ers (“triple quad”) with three quadrupole stages, and Q-TOF mass
pectrometers, which combine selection and fragmentation using
uadrupoles and time-of-ﬂight (TOF) analyzers. The TOF analyz-
rs provide greater mass accuracy than quadrupoles and are very
opular for metabolomics analyses (Fig 1C).
Ion traps use oscillating electric ﬁelds within a variety of two-
nd three-dimensional geometries to trap ions for detection and
on dissociation. Ion traps are very powerful for ion dissocia-
ion studies and also to accumulate selected ions for subsequent
igh-resolution analysis in combination with ultra-high resolution
ass detectors. Ultra-high resolution mass detectors measure mass. D. Ultra-high resolution accurate mass (UHRAM) mass spectrometers resolve ions
ion and mass accuracy simpliﬁes separation requirements and provides improved
ma. Panels B–D were modiﬁed from [18] with permission.
through Fourier transformation of the image current of ions cycling
within an electromagnetic ﬁeld. These include ion-cyclotron res-
onance (ICR) mass spectrometers and Orbitraps (Thermo-Fisher).
The ultra-high resolution and mass accuracy provide an advantage
for high-resolution metabolomics by decreasing the separation
requirements of GC–MS and LC–MS, and increasing the range of low
abundance chemicals that can be measured compared to MS/MS
(Fig 1D). Some of the Q-TOF instruments provide similar accurate
mass for high abundance ions but are not as effective in resolving
ions with very similar mass at low abundance. An advantage of Q-
TOF instruments lies in fast scan speeds, and there is likely beneﬁt
from a union of technologies to sequence the exposome.
Many factors inﬂuence ability to accurately measure chemicals
of interest, and most are not unique to MS,  e.g., methods of sample
collection and storage, avoidance of contamination and dynamic
range of detection. For MS,  additional factors include ionization,
ability to resolve chemicals prior to or during analysis, and ability
to measure m/z accurately. With advances in all aspects of sepa-
ration sciences, spectrometry and physical and chemical analysis,
32 D.P. Jones / Toxicology Reports 3 (2016) 29–45
Fig. 2. High-resolution metabolomics (HRM) for advanced chemical proﬁling. A. The human metabolome is complex and likely to include >400,000 environmental chemicals.
B.  The cost for measurement of large numbers of environmental chemicals is impractical with targeted analytical methods but can be affordable if large numbers of chemicals
are  measured in a single analysis. C. High-resolution metabolomics uses high-resolution mass spectrometry with liquid chromatography to measure >20,000 chemicals based
upon  high mass resolution and high mass accuracy. D. An important advantage of high-resolution mass spectrometry is that data in proﬁle mode contains more information
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ehan  commonly used centroid mode. The centroid mode decreases the m/z window
ons  resolved by a high-resolution (High Res) mass spectrometer are not resolved b
nly  3 of 9 ions are detectable.
nalytical techniques are available to address almost any complex-
ty concerning targeted analyses of chemicals of interest. Despite
his, there is no available strategy to provide comprehensive cov-
rage of chemicals in biological space, i.e., to accomplish chemical
easurement in the same way as one can obtain comprehensive
overage of base-pair sequences in genomic space.
In fairness, the scope of analytical chemistry never included
ntent to provide platforms to measure everything; such a thought
s absurd given that chemical space appears to be inﬁnite [21].
erhaps more relevant, half a century ago, public concern over
ealth effects of chemical pollutants led to government policies to
imit exposures. This occurred long before current analytical tech-
ologies were available, and policies were developed based upon
echnologies available at the time. And even with more limited
echnology, an effective strategy was developed to identify haz-
rds, evaluate sources and risks of exposure, and develop means
o monitor and limit hazardous exposures. This approach involved
rioritization of hazards and risks, focusing on known hazards and
eveloping rigorous analytical methods for these. This approach
s sound and proved effective, using resources wisely for targeted
nalysis of chemicals of greatest concern.
This targeted strategy is limited by cost to address possible risks
rom large numbers of hazardous chemicals. Limitations are also
vident to discover chemicals that are hazardous at lower expo-ero, thereby being much more efﬁcient for data storage. As this simulation shows,
w-resolution (low Res) instrument. When the latter is expressed in centroid mode,
sure levels, and also those that are toxic due to chemical–chemical
or gene-environment interactions. Small molecules present in
biologic systems are cumulatively described as the metabolome,
and include essential nutrients, gene-directed products of these
nutrients, dietary constituents, products of intestinal microbes,
drugs and related metabolites and commercial and environmen-
tal chemicals (Fig 2A) [18]. About 100,000 agents are registered for
commercial use with the US Environmental Protection Agency, and
these plus drugs, supplements and related microbial and geother-
mal  products, suggest that the environmental metabolome is likely
to consist of 400,000 or more chemicals. Although most of these
pose no environmental health risk, increases in prevalence of many
diseases over the past half-century indicate that unidentiﬁed haz-
ards are present [36].
Analysis of costs shows that targeted analysis of large num-
bers of chemicals broadly in populations is unaffordable (Fig 2B).
For instance, if analyses are done individually, total cost increases
as a function of the number of chemicals measured (Fig 2B). This
restricts the number of chemicals measured to the most hazardous.
For difﬁcult chemicals, like dioxins, cost can be >US$4000 per sam-
ple, so global sampling of populations is impossible. Consequently,
routine environmental chemical surveillance by targeted meth-
ods is affordable only for a relatively small number of the most
hazardous chemicals, and measurement of these is limited to rep-
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esentative sampling for populations. There is no opportunity to
outinely monitor lesser hazards, evaluate mixtures for which no
ompelling evidence for hazard is present, or address unrecognized
azards.
A lesson from the Human Genome Project is that focus on a
mall number of hazards is not good enough. Prior to sequenc-
ng the human genome, many believed that knowledge of genetic
ariations would rapidly lead to understanding human disease
ecause mutations like those causing phenylketonuria or sickle cell
isease produced very evident disease consequences. As genome-
ide association studies (GWAS) became available for common
iseases, however, results showed that most genetic variations
ssociated with disease have a small effect size. Individual vari-
tions often account for less than 1% of the overall risk of disease,
nd genetic associations of disease are not detectable unless studies
re conducted with 20,000 or 30,000 individuals. If environmental
xposures similarly have small effect size, where individual chem-
cals each contribute to less than 1% of overall risk of disease, then
argeted analysis of high-risk chemicals in small populations pro-
ides no way to detect or monitor this type of exposure-related
isk. Changes in prevalence of obesity, diabetes, autism, childhood
rain cancer, breast cancer, Alzheimer’s disease, parathyroid dis-
ase, and other disease processes could be linked to changes in
ultiple unidentiﬁed chemical exposures, each with small effect
ize. Hence, there is need to approach environmental causes of
isease in the same way that geneticists found necessary to under-
tand genetic factors: develop a comprehensive framework which
an be applied to large populations.
. High-resolution metabolomics
An advanced but demanding (liquid helium temperature) mass
pectrometry method was developed in 1974 that provided a
oundation to overcome critical limitations to measurement of
housands of small molecules in an affordable manner. Comisaro
nd Marshall [3] developed Fourier-transform ion cyclotron reso-
ance (FT-ICR) MS,  an approach in which ions were cycled within a
igh-ﬁeld electromagnet, to enable separation of ions with m/z dif-
ering by <1 ppm. This means that instead of measuring an m/z with
he accuracy 200.0 ± 0.1, the ion would be measured with the accu-
acy 200.0000 ± 0.0002. For many low-molecular mass chemicals,
ass accuracy can be sufﬁcient to predict elemental composition.
easurement of ions with this ultra-high mass resolution and mass
ccuracy provides a way to bridge between targeted analyses of
hemicals of known importance and capture of information about
ncharacterized chemicals present in biologic systems (Fig 2C).
bout 10 years ago a new form of ion trap (Orbitrap; ThermoFisher)
as introduced which also provides ultra-high resolution and accu-
ate mass detection but is less demanding for operations (does
ot require liquid helium). The detection and conversion to m/z
lso involves Fourier transformation so these can be generically
escribed as FT instruments to distinguish them from time-of-
ight (TOF) methods, some of which are also high-resolution
nstruments [26]. ThermoFisher has several FT instruments and
everal manufacturers (AB Sciex, Agilent, Brucker, Shimadzu) mar-
et high-resolution TOF instruments; comparison of the types of
igh-resolution instruments is available [26].
.1. Advantages of ultra-high resolution MS
The importance of the mass accuracy and mass resolution is
pparent when considering measurement of metabolites in the
entral human pathways of the Kyoto Encyclopedia of Genes and
enomes (KEGG) database [19]. Of approximately 2000 metabo-
ites, >95% have unique m/z  when measured with ±5 ppm accuracy.orts 3 (2016) 29–45 33
This substantially simpliﬁes analysis because most of these can be
measured with minimal chromatographic separation. With known
chemicals in common biologic samples, such as plasma, this often
eliminates need for ion dissociation (MSn) mass spectrometry for
identiﬁcation and measurement. In development of procedures, we
studied ﬁve aminothiol metabolites differing by more than 3 orders
of magnitude in abundance in human plasma [15]. We  found that
these could be resolved and identiﬁed without ion dissociation MS
and that quantiﬁcation was  comparable to other analytical meth-
ods [15].
Building upon this quantitative framework, which showed that
the intensity of accurate mass m/z features could be directly
calibrated to yield reliable concentration measurements, we devel-
oped data extraction algorithms to enhance measurement of other
chemicals [48]. New data extraction algorithms were needed to
maximize information capture on low abundance metabolites. For
extraction of low abundance m/z features, many ions are detected
within 0.1 AMU  of each other (Fig 2C). Data can be extracted in
different ways, with a commonly used data extraction producing
centroid mode data in which m/z for a feature is collapsed to zero
width to decrease size of data ﬁles for processing and storage. In
contrast, extraction of data in proﬁle mode yields better data recov-
ery than centroid mode because more information is retained for
signals as a function of m/z (Fig 2D). Use of centroid mode for data
extraction can result in merger of different ions into a single m/z,
easily mistaken for a single, relatively abundant chemical; in some
cases, signals can be merged to create the m/z of a chemical that
is not present. For analyses of samples with unidentiﬁed and/or
unknown low abundance environmental chemicals, proﬁle mode
provides a more reliable starting point for data extraction [48].
3.2. Improved data extraction algorithms
Starting with proﬁle mode data, adaptive processing algo-
rithms for liquid chromatography-mass spectrometry (apLCMS)
were developed to improve the number and reproducibility of
detected metabolites [48]. The improvement in chemical detec-
tion was apparent immediately, with an increase from about 300
chemicals to more than 1500 (Fig 3A). apLCMS uses the data char-
acteristics, such as noise level and peak shapes, to guide data
extraction. Improvements have included xMSanalyzer, a routine to
use different extraction parameters and statistical ﬁlters to merge
results to enhance coverage and reproducibility [42]. A hybrid ver-
sion of apLCMS has also been developed to support targeted data
extraction in combination with untargeted extraction [49].
3.3. Applications for precision medicine
Application of apLCMS to human plasma samples measured on
an FT-ICR MS  with a 10 min separation on anion exchange chro-
matography showed that >1500 reproducible metabolic features
were measured, where a feature is deﬁned as an accurate mass
m/z with associated retention time (RT) and ion intensity [16].
This deﬁnition of a metabolic feature is sufﬁciently robust to allow
reproducibility of measurement at different times and on different
instruments. By inclusion of internal standards to allow calibra-
tion of RT, unidentiﬁed chemicals can be retrospectively identiﬁed
based upon the accurate mass m/z and RT. Because the >1500
features include amino acids, energy metabolites, vitamins and
coenzymes, lipids and many other metabolites relevant to human
health, the analytical platform provides a practical approach for
personalized medicine [16].
34 D.P. Jones / Toxicology Reports 3 (2016) 29–45
Fig. 3. Recent improvements in high-resolution metabolomics. A. Improved coverage of chemicals in human plasma have occurred over the past several years due to improved
data  extraction algorithms, improved instrumentation and improved standard operating procedures (graphic based upon ﬁgure prepared by DI Walker). B. Multiple steps
have  been introduced to improve consistency and data quality. C. Cross laboratory comparisons provide an effective approach to verify correct identiﬁcation and evaluate
quantiﬁcation of metabolites. Phenylalanine (Phe) and threonine (Thr) comparisons were between HRM and amino acid measurements by the Emory Human Genetics
Laboratory. Creatine and cortisol comparisons were between HRM and measurements by Metabolon. D. Quantiﬁcation of environmental chemicals in human plasma by
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opyright Clearance Center.
.4. Improved affordability of chemical proﬁling with HRM
Cost considerations are highly relevant to analytical methods,
nd the aminothiol method described above is a useful exam-
le. The high-resolution mass spectrometry method required only
0 min  for analysis, plus 10 min  wash time, to obtain the same
easurement as obtained in one hour by HPLC with ﬂuorescence
etection. However, the high-resolution mass spectrometry analy-
is required averaging of duplicates to obtain the same data quality,
nd the cost was  US$25/chemical, approximately ﬁve-fold the cost
f the HPLC method (US$4.40/chemical). However, if 2000 chem-
cals were measured, the cost would be only US$0.06/chemical.
hus, value is derived from simultaneous measurement of many
hemicals.
.5. Limitations and strategies to improve HRM
During recent years, we have focused on costs, coverage and data
uality as criteria to improve HRM. Although details are beyond the
cope of the present summary, some points warrant comment. Cost
er analysis is approximately cut in half by using a dual chromatog-
aphy setup in which one LC column is washed and re-equilibrated
hile the mass spectrometer is used to analyze a sample on anotherstandards and matched product ions in ion dissociation spectra. Quantiﬁcation was
thod of additions. Figures from [11] were used with permission conveyed through
column [40]. With this approach, we were able to use two types
of columns to increase detection to more than 4000 chemical fea-
tures [40]. This was further increased to >10,000 by acquisition of
an LTQ-Velos Orbitrap and dedicating use to HRM (Fig 3A).
With this conﬁguration, data extraction using xMSanalyzer [42]
with apLCMS [48] resulted in >20,000 chemical features. This num-
ber can be increased to >100,000 by allowing extraction of chemical
features found in only a small fraction of the samples. This can be
important, for instance, for chemicals found in only 1% or less of the
population. The actual number of chemicals measured is difﬁcult
to determine because many chemicals are detected in different ion
forms, e.g., H+ and Na+. Most ions detected in plasma by HRM are of
relatively low abundance, however, and these appear to be present
only as one form. Consequently, >100,000 ions detected probably
reﬂects >50,000 chemicals in the sample. By varying extraction
parameters, results indicate that >300,000 ions are detected (K
Uppal, unpublished), and by combining data from analyses using
different chromatography and ionization methods, results indicate
that >800,000 ions are detected (DI Walker, unpublished). Thus,
the analytical capabilities with HRM are good enough to set a mile-
stone for analytical chemistry: capability to analyze one million
chemicals in small microliter volumes of plasma and other biologic
materials.
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.6. Development of standard operating procedures (SOP)
With development of effective methods for measurement of
uch a large number of chemicals, focus must switch to quality of
ata. For this, we adopted LC–MS and data extraction procedures to
outinely measure 20,000 ions [42]. For about 1000 ions, including
ost of the amino acids and many other intermediary metabolites,
eproducibility of HRM is good enough (CV < 10%) so that technical
eplicates are not needed. Our tests showed, however, that most
/z features had greater CV so that replicate analyses were needed
o improve data quality. We  adopted an SOP (Fig 3B) with three
echnical replicate analyses of each sample. With xMSanalyzer,
pproximately 20,000 m/z features are obtained with median CV
f about 25%. Because triplicate analyses are performed, the accu-
acy of measurement is better expressed by the standard error of
he mean, which is <15%. Under these conditions, the cost for each
hemical feature is less than US$0.005. Newer high-ﬁeld Orbitrap
nstruments have improved scan speeds, and our initial studies
ndicate that lower cost can be obtained with similar quality using
maller columns, shorter run time and ﬁve replicate analyses of the
ame sample. Additionally, our comparison of different combina-
ions of liquid chromatography columns and ion sources show that
ual chromatography using positive ESI with HILIC and negative
SI with C18 provides the most extensive coverage within a single
nalysis (DI Walker et al., unpublished).
I view the routine measurement of 20,000 metabolites in a
uman sample as a critical threshold for personalized medicine.
lready within the sequences of 20,000 genes, information is avail-
ble to predict risk of many diseases. Similarly, knowledge of
nvironmental chemical exposures can be used to predict disease
isk so that, in principle, an analytical platform providing inter-
al doses of environmental chemicals advances capabilities for risk
rediction. Furthermore, speciﬁc gene-environment interactions
ave been identiﬁed so that the combination of detailed metabo-
ite proﬁles with detailed genetic information can be expected to
rovide an enhanced analytic structure for risk evaluation and pre-
iction.
Genetic information alone can provide unambiguous identiﬁ-
ation of an individual and is useful for risk prediction, but in
he case of identical twins, where genetic information is identical,
onsiderable discordance in health outcome can still occur. These
ifferences appear to be due to differences in individual exposures.
n terms of health prediction, combination of information on 20,000
uman genes with information on 20,000 metabolites from HRM
rovides a genome × metabolome interaction network of 400 mil-
ion interactions, without considering interaction effects. In our
npublished analyses of this type, data appear to be sufﬁcient to
eﬁne individual genome-metabolome interaction structure in an
nambiguous manner. Because the number of interactions (400
illion) is greater than the number of Americans (310 million), this
ombination appears sufﬁcient to develop precision medicine pro-
rams that are truly personalized. Thus, the practical implication
f an affordable means to routinely measure 20,000 chemicals in a
lood or urine sample is that with a commitment to obtain genetic
nformation, a sufﬁcient foundation is available to create a powerful
recision medicine system in which environmental exposures are
ncluded within predictive, diagnostic and management models.
.7. Focus on data quality to obtain affordable high-throughput
nalysis
With this prospect of affordable high-throughput chemical pro-
ling now approaching reality, data quality must be critically
valuated and substantiated. Although traditional analytical chem-
stry methods are expensive, the quality standards are very high.
o consider adoption of a new approach, key questions mustorts 3 (2016) 29–45 35
be addressed concerning accuracy and reproducibility of chemi-
cal detection, identiﬁcation and quantiﬁcation. Most of these can
be satisfactorily addressed but require adoption of different, and
somewhat less ﬂexible laboratory practices.
Analytical facilities differ in the types of samples analyzed, the
chemicals measured and the demands for precision in identiﬁcation
and quantiﬁcation. To enable capture of the large number of chem-
icals by HRM, some important compromises must be made. One is
the dedication of use of powerful instruments to a single purpose.
By restricting an instrument to one or a small number of very similar
matrices (e.g., plasma, food extracts, liver biopsy, etc.), variations
in response characteristics can be readily monitored. Additionally,
if only one type of sample (e.g., serum or plasma) is analyzed on an
instrument, then there is little chance for contamination by chem-
icals present in laboratory toxicology experiments, food extracts,
etc. Although difﬁcult to precisely verify, the sensitivity to detect
low abundance chemicals with exactly the same method appeared
to nearly double when we transitioned from a common use to a
dedicated use instrument. The practical meaning is that analyti-
cal facilities using HRM probably need at least two high-resolution
instruments, one for dedicated use to the primary matrix and a
second for multiple application use. In this regard, newer instru-
ments are replacing many FT-ICR MS  and earlier LTQ-Orbitrap MS
used for proteomics, and this has created an availability of high-
resolution instruments that can be re-purposed for high-resolution
metabolomics projects.
3.8. Chemical identiﬁcation strategies
Traditionally, veriﬁcation of chemical identity is obtained by
direct comparison to analysis of authentic standard on the same
instrument under the same conditions, usually on the same day
within the same sample batch. We  avoid this common approach
for two reasons. Although authentic standards are frequently >99%
pure, they invariably are contaminated with some level of impuri-
ties. While this is not of concern in a targeted analysis, this poses
a risk of introduction of low-abundance contaminants in untar-
geted analyses. The advanced data extraction algorithms increase
dynamic range of detection to nearly eight orders of magnitude,
so contamination by very minor components in puriﬁed standards
cannot easily be evaluated. Thus, to avoid contamination of sam-
ples with unknown impurities, a simple procedure is to follow the
same rule as above, maintain one instrument for routine analysis
of a common matrix and perform chemical identity studies on a
different but comparable system. By doing such studies of chem-
ical identity independently of the ﬁrst analysis, one also conﬁrms
reproducibility of detection on a different instrument with different
LC column and solvents. By doing this, reproducibility is conﬁrmed
in a way that can be translated to different instruments in different
facilities and measured at different times.
Several tools are available to aid identiﬁcation of chemi-
cals and discussed elsewhere [7,20,24,39]. Common principles
are used and some are brieﬂy discussed here. A key founda-
tion for HRM involves the mass resolution and mass accuracy
of the instruments. Mass resolution and resolving power refer
to the separation of mass spectral peaks and have been deﬁned
by IUPAC (see http://ﬁehnlab.ucdavis.edu/projects/Seven Golden
Rules/Mass Resolution) for discussion. Higher values refer to better
resolution, with quadrupoles and lower resolution TOF instru-
ments having 10,000 resolution, high resolution TOF having 60,000
resolution, Orbitraps having about 100,000 resolution, and Fourier-
Transform Ion-cyclotron Resonance (FT) instruments having up
to 1000,000. The latter instruments (Orbitrap, FT) are sometimes
referred to as “ultra-high resolution accurate mass (UHRAM) mass
spectrometers.
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For high-resolution FT instruments (LTQ-FT; LTQ-Velos Orbi-
rap) operating at 50,000–60,000 resolution, database match
ithin 10 ppm for common ionic forms (e.g., H+ and Na+) is often a
uitable place to begin. In direct comparisons of data collected from
uman plasma on an LTQ-FT comparing 50,000 resolution (10 min
C run) and 100,000 resolution (20 min  LC run) and on an LTQ-Velos
rbitrap comparing 60,000 (10 min  LC run) and 120,000 (20 min  LC
un), we found that the lower resolution runs for 10 min  captured
0–95% of the ions detected at the higher resolution. Instrument
peciﬁcations indicate that <5 ppm accuracy should be obtained,
ut we found that improved ion detection was obtained by increas-
ng the ion count to higher values than recommended; this results
n improved detection of low abundance ions but also results in
eterioration in mass accuracy. Speciﬁcally, on the LTQ-FT and LTQ-
elos Orbitrap, m/z for internal standards often are 8 ppm from
he exact mono-isotopic mass. For the Q-Exactive or Q-Exactive-
F operating at 70,000–140,000 resolution, 5-min LC runs with
maller injection volumes and smaller LC columns provide better
ata, typically with detected m/z  within 5 ppm of the monoisotopic
ass.
In practice, greater tolerance is sometimes needed because the
omplexity of instrumentation and data extraction do not always
ield the same precision for all ions. Routines are now available
hich allow grouping of ions according to likelihood that they are
erived from one chemical. If such ions correlate in intensity among
amples, this provides conﬁdence that the precursor ion is correctly
elected. Detection of correlated isotopic forms, e.g., 12C and 13C
orms, also provides such conﬁdence. With 20,000 ions detected
y high-resolution MS,  however, most of the ions have relatively
ow intensity and do not have strong correlations with high abun-
ance ions. Consequently, most low abundance ions appear to be
erived from unique, low abundance chemicals rather than being
ow-intensity ions derived from high abundance chemicals. This
haracteristic is of considerable importance for exposome research
ecause it suggests that humans are exposed to a large number of
ow abundance, uncharacterized chemicals. Indeed, every MWAS  of
isease that has been performed by our research group has found
ccurate mass m/z features that do not match any metabolite in
etlin, HMDB or KEGG databases.
.9. Rigid 24/7 work schedule
In characterization of conditions to establish SOP for high-
hroughput metabolomics, we found much better consistency of
ata when using a continuous 24-h per day, seven day per week
nalysis rather than work schedules with interruptions of analysis.
hus, I feel that a commitment to a continuous 24 h per day, 7 days
er week analysis is necessary, and this structure (Fig 3B) can limit
exibility in an analytical laboratory. Analytical variation occurs
ue to stopping and starting chromatography because physical
nteractions and chemical reactions are ongoing on chromatogra-
hy columns. These variations are minimized by using a rigorously
nforced analytical strategy, with a ﬁxed number of wash-in anal-
ses, a ﬁxed number of total analyses, and scheduled shut-down
or cleaning, servicing, replacement of columns and recalibration.
 byproduct of the routine scheduling of cleaning and replacement
f serviceable parts is that autosamplers, LC systems and columns
arely fail within a 30-day analytic sequence, supporting consistent
nalyses of up to 600 samples in triplicate on two columns within
 single run.
.10. Cross-laboratory comparisonsWith a stable analytical structure operated under routine condi-
ions, known metabolites elute reproducibly so that conﬁrmation of
dentity within each sample is unnecessary. To support such routineorts 3 (2016) 29–45
use of accurate mass and retention time as a basis for identiﬁcation,
however, rigorous identiﬁcation and veriﬁcation of selective detec-
tion is required. Several approaches are available, with no single
approach universally acceptable. A very convenient approach is to
analyze the same samples by HRM and another validated platform
(Fig 3C). We have done this for different chemicals with six differ-
ent analytical facilities, with some examples provided (Fig 3C) for
amino acids measured by the Emory University Genetics Labora-
tory and creatine and cortisol measured by Metabolon (Research
Triangle Park). Such comparisons are useful both for identiﬁcation
and to test reliability of quantiﬁcation. We perform such analyses
in a randomized and blinded manner to assure integrity of results.
So far, the results of such comparisons are re-assuring in terms
of data reliability; despite this, some inconsistencies are present,
and these provide useful information concerning needs for further
identify veriﬁcation.
3.11. Honest interpretation, honest reporting
Many mass spectral analyses are problematic because of inabil-
ity to separate or distinguish chemicals. For example, both d- and
l-aspartic acid (Asp) occur in biologic systems; even though l-Asp
is more common, one cannot unequivocally identify l-Asp without
appropriate consideration of d-Asp. Most analytical laboratories
adopt a practical approach to assume that the more common form
is the one measured and/or do not specify stereospeciﬁcity or posi-
tional isomers when the methods do not support such distinction.
Designations can be used such as Leu/Ile, for methods where leucine
(Leu) and isoleucine (Ile) are known to be present but are not
resolved. Many lipids and environmental chemicals are problem-
atic because isobaric (same mass) species exist. The practical matter
is that if one form is predominant, i.e., represents 95% or more of
the signal, then the measurement is principally of that chemical
regardless of the contribution of other lower abundance ions.
3.12. Chemicals of low abundance or infrequent occurrence
Challenges exist for chemical identiﬁcation of ions that are
not uniformly present in samples from different individuals. For
instance, if a chemical is only found in 1% of samples, then param-
eter settings are needed to allow detection, and large population
sizes are needed to evaluate whether health risks are associated
with that chemical. MS/MS  studies can only be performed on sam-
ples for which the ion is detected, and the volume of sample
available can limit ability to pursue identiﬁcation. For low intensity
ions, identiﬁcation using MS/MS  can be difﬁcult if multiple ions are
present within the ion selection window for MS/MS  (see Fig 2C,
where 0.5 AMU  isolation window contains many low-abundance
ions). In such cases, deconvolution MS/MS  is needed to allow recon-
struction of ion dissociation spectra [27]. These issues illustrate
need to establish a universal surveillance system for study of pop-
ulations that are large enough to address low abundance chemicals
with low prevalence.
3.13. Quantiﬁcation
Quantiﬁcation is the holy grail of analytical chemistry. With
genomics, transcriptomics and proteomics, considerable advances
in knowledge have been made without absolute reference mea-
surements. Similarly, HRM has mostly relied upon relative
intensities, with pooled reference samples analyzed regularly to
evaluate consistency of response characteristics. This is not ideal,
but standard curves and daily high and low quality control analyses
are not feasible for thousands of chemicals. To address this chal-
lenge for exposome research, a reference standardization protocol
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as developed for HRM analyses [11]. This relies upon commonly
sed methodology of surrogate standardization.
Surrogate standardization is a useful approach that involves
uantitative calibration of a target chemical relative to a known
mount of a reference chemical. For instance, if a stable isotopic
orm of palmitic acid were added as an internal standard to quan-
ify palmitic acid, it could also be used as a surrogate standard to
stimate myristic acid and stearic acid concentrations. Inclusion of
uch reference chemicals as internal standards is extremely valu-
ble for quantiﬁcation of chemicals when multiple extraction or
rocessing steps are required. Although frequently not appreciated,
his “gold standard” approach, as used for quantiﬁcation of analy-
es done by tandem mass spectrometry, is a single-point calibration
ethod. Linearity is assumed but not explicitly established during
nalysis, and no upper and lower quantiﬁcation range is deter-
ined. With such analysis, the error of the measurement includes
 multiplication of the error for each component.
Common use of stable isotopic internal standards for quantiﬁ-
ation has, therefore, established a de facto single-point calibration
s an acceptable alternative to standard curves for MS-based quan-
iﬁcation. This is important because with this principle, one can
eadily convert MS  signal intensities to absolute concentrations
y referencing to calibrated samples, such as National Institute
f Standards (NIST) Standard Reference Material 1950 (SRM1950).
ecause SRM1950 has concentrations certiﬁed, use of this reference
aterial for single point calibration provides a versatile approach
or absolute quantiﬁcation of any chemical present within this sam-
le. In combination with cross-platform validation studies (Fig 3C),
ne can verify that such approaches are valid and yield useful quan-
itative data [11].
. HRM for environmental chemical analysis: standardized
orkﬂow
The step from clinical metabolomics (discussed above) to envi-
onmental chemical analysis is small yet challenging. Clinical
etabolomics includes hundreds of metabolites present in the
icromolar range. Many of these have been extensively stud-
ed. Many have metabolic precursors and products, which are
tructurally related, simultaneously measureable and also well
haracterized. Additionally, mammalian species have very simi-
ar central pathways of metabolism so the extensive knowledge
f rodents and other species provides a resource for interpretation.
n contrast, environmental chemical abundance in human samples
s typically nanomolar or sub-nanomolar, often pushing limits of
etection [35]. Further, xenobiotic metabolism is more highly vari-
ble among species and among individuals [33]. For analyses to
easure exposures in individual human samples, this limits ability
o rely upon data from other species, and sometimes limits ability
o trust population-based human data.
Despite this, application of the principles described above shows
hat environmental chemicals can be identiﬁed in human sam-
les [33] and that useful quantiﬁcation can be obtained (Fig 3D).
or clinical metabolomics, high-resolution metabolomics methods
etect metabolites in most metabolic pathways [18], with accu-
ate mass matches to more than half of the metabolites in KEGG
uman metabolic pathways. These central pathways include only
000 metabolites, however, and this represents only 10% of the
0,000 ions routinely measured by HRM. Even accounting for multi-
le ions from individual chemicals, results show that large numbers
f uncharacterized chemicals exist in plasma. Hence, the results
uggest that application of HRM could provide useful new infor-
ation on human exposures, and this has been substantiated by
tudies of Parkinson disease [38], age-related macular degenera-orts 3 (2016) 29–45 37
tion [32], glaucoma [2], tuberculosis [8], HIV-1 infection [6] and
alcohol abuse [31].
The standardized workﬂow developed during the past several
years for use of HRM departs substantially from targeted environ-
mental chemical analysis. Part of this is the result of the intent
to provide a more affordable and powerful clinical metabolomics
capability. Some of the procedures are brieﬂy described here to
expose details often not discussed in typical research manuscripts.
4.1. Sample collection and storage
This is the most uncontrolled variable for all aspects of analyt-
ical sciences. Samples collected under different work conditions
by different individuals and with varying instrumentation, storage
conditions and timing, are outside of the control of the analyti-
cal facility. There is no simple way to ascertain whether a sample
was badly corrupted before delivery to the analytical laboratory.
Thus, rather than potentially introducing bias by rejecting a sam-
ple, we  use a simpler approach, to assume that those who collected
the samples followed appropriate protocols, labeled samples cor-
rectly and discarded or noted samples thought to be corrupted.
We  analyze every sample and use quality control (total ion inten-
sity; correlation of triplicate analyses) and downstream statistical
criteria to evaluate data for exclusion. Such downstream criteria
can include glucose (blood samples that are allowed stand at room
temperature for long periods before centrifugation frequently have
very low glucose concentration), heme (samples with extensive
hemolysis have high heme content) or oxidized sulfur-containing
chemicals (cystine oxidation to cystine sulfoxide and cystine sul-
fone occurs upon long-term storage).
4.2. Sample processing for metabolomics
Many small molecules bind to protein and cannot be separated
and measured unless the protein is removed. Therefore the ﬁrst
step for most analyses of small molecules in biological samples is
to remove protein. However, every sample manipulation has differ-
ential effects on recovery of chemicals so every effort must be made
to perform this step consistently. Targeted methods include index
chemicals to evaluate recovery at each step, but this is only effec-
tive for index chemicals with properties similar to the chemicals
being analyzed. When thousands of chemicals are being analyzed,
veriﬁcation of recovery for each becomes impossible. Therefore, we
adopted a simple operational method for preparation of 20 research
samples and a pooled reference sample together for analysis, using
very consistent processing.
To remove protein, 120 l of highest purity acetonitrile (or
methanol) at 0 ◦C containing a mixture of stable isotopic stan-
dards is added to 60 l of each research or reference sample,
followed by timed mixing. Acetonitrile and methanol are similar
in terms of protein removal but acetonitrile is better in removal
of oligonucleotides. Samples are allowed to stand on ice in the
dark for 30 min  prior to centrifugation at the top speed in a micro-
centrifuge to remove protein. This largely removes protein and
extracts a consistent amount of lipophilic compounds from the
lipoproteins. However, it should be noted that this extraction is
optimized to obtain a broad spectrum of polar and non-polar chem-
icals; an extensive literature exists for targeted lipidomics research,
and other extraction procedures can improve extraction of dif-
ferent classes of lipids. After protein removal, samples are then
loaded onto a refrigerated autosampler and analyzed as previously
described in detail [10]. Validation studies for time in the autosam-
pler showed parallel analyses of a sample set in opposite order
resulted in comparable data [16]. Using this approach, the internal
standards provide multiple internal standard references for qual-
ity control, retention time calibration and veriﬁcation of instrument
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erformance. This minimal processing approach is limited in that
here is no enrichment step for low abundance chemicals, and some
hemicals are not well extracted. On the other hand, for the >20,000
ons that are measured, they are analyzed in a routine manner with
ittle opportunity for failure. Integration with data obtained using
ther platforms, e.g., GC–MS, LC–MS/MS, will provide a robust core
ata structure as a reference for all types of exposure and pheno-
ypic data.
.3. Liquid chromatography-high resolution mass spectrometry
Only MS1 (precursor ion spectra) data are captured during our
outine analysis. This was a practical decision to simplify the pro-
ramming requirements for data extraction. As indicated above,
ost common intermediary metabolites have unique elemental
omposition and can be unambiguously measured due to the mass
esolution and mass accuracy of the instrument. As newer instru-
ents and data extraction algorithms are developed, this analytical
tructure can be updated, especially with inclusion of MS/MS  on
argeted ions.
.4. Data extraction
MS  data are processed in proﬁle mode to .cdf ﬁles and
xtracted with apLCMS [48] using xMSanalyzer [42]. A hybrid tar-
eted/untargeted extraction routine is also available which allows
nput of targeted environmental chemical lists to enhance repro-
ucibility of environmental chemical data extraction [49]. Data
utput from xMSanalyzer is provided in a form that can be used
n popular spreadsheet and database formats. Data include quality
ontrol criteria; each sample is analyzed in triplicate and for each
/z feature in each sample, a coefﬁcient of variation (CV) is calcu-
ated. Median CV, % missing values and a combined Quality Score
s provided for each m/z  (Fig 4A). Initial testing showed that use
f ﬁve technical replicates further improves data quality and also
llows useful information to be captured on lower abundance ions.
.5. Bioinformatics and biostatistics
A wide array of bioinformatic and biostatistical tools are avail-
ble for data analysis. We  commonly use LIMMA  in R programming,
ith false discovery weight adjustment [14] for initial statistical
esting for group-wise differences, metabolome-wide associations
ith speciﬁc environmental chemical exposures, or metabolome-
ide correlations with physiologic, clinical or other parameters of
nterest (see below). This generates Manhattan plots of–log p versus
/z to visualize signiﬁcant features (Fig 4B and C). For many pur-
oses, it is useful to see the signiﬁcant features plotted both as
 function of m/z  and retention time, with color-coding to distin-
uished direction of effect [12]. Because one must protect against
oth type 2 as well as type 1 statistical error, a useful practice
s to identify raw p with color and FDR with broken horizontal
ines (Fig 4B and C). While statistical testing is useful to evaluate
/z that differ, partial least squares-discriminant analysis (PLS-DA)
rovides an approach to rank m/z in terms of their contribution
o separation (see section IV.B). Features that are both signiﬁcant
ollowing FDR correction and are among the top in contributing
o PLS-DA separation are often of greatest interest for subsequent
tudy.
.6. Graphical presentation of dataAfter a list of features of interest is generated, multiple
pproaches are available for annotation and curation of chemical
dentity and linkage to pathways and functional networks. This is
llustrated by ﬁgures from a recent metabolome-wide associationorts 3 (2016) 29–45
study (MWAS) of pulmonary tuberculosis (Fig 5). The MWAS  data
are plotted as a Manhattan plot (Fig 5A), and box and whiskers plots
are generated for metabolites that differ (Fig5B). These data are
then used to perform a 2-way hierarchical cluster analysis of the
distribution of signiﬁcant features among subjects (Fig 5C). This
is very useful to see how well the selected features classify the
individuals and also see how similarly the features are distributed
among the individuals. The clusters of metabolites are often closely
related, including multiple ions from a single chemical (e.g., Na+
and H+ forms), multiple metabolites from common pathways [(e.g.,
phenylalanine (Phe) and tyrosine (Tyr)] and metabolites with very
similar properties (e.g., different phosphatidylcholines). Among the
quickest ways to identify pathways is to match the high-resolution
m/z to predicted ions of chemicals in HMDB (http://www.hmdb.
ca), Metlin (https://metlin.scripps.edu/index.php) or other online
metabolomics database. Using KEGG compound identiﬁers, one
can query the KEGG compound database for KEGG Pathway or
KEGG Brite classiﬁcation (Fig 5D). This is often inefﬁcient, however,
because there are many matches to some m/z and there is no sta-
tistical test to enhance conﬁdence. Thus, a better approach is to use
a pathway analysis program such as Mummichog [22], MetaboAna-
lyst [46] or MetaCore (thomsonreuters.com/metacore/) to perform
pathway analyses with statistical testing routines. Pathway anal-
ysis can be challenging but is extremely valuable because this
analytical structure allows linkage of exposures to biologic effects,
i.e., perturbations of metabolism that are signiﬁcantly associated
with a chemical or chemical metabolite that is directly measured
in the same biologic samples.
5. Paradigms for use of HRM in exposome research
In an initial examination of combined exposure surveillance and
bioeffect monitoring, we compared seven mammalian species with
considerable differences in environment [33]. The hypothesis was
that because humans have more varied exposures than animals
housed in research facilities, humans would have more variable
chemical content in plasma. The results showed, however, that
research animals have exposures to some of the same insecticides,
ﬁre retardants and plasticizers, as humans. Additionally, the num-
ber of metabolites detected was similar, suggesting that dietary
and microbiome chemicals also contribute to the metabolomes of
other species in the same way as in humans. Finally, cluster analysis
showed that some metabolites had greater interspecies variation
than intraspecies variation; environmental chemicals and metabo-
lites used for detoxiﬁcation, such as glutathione, were present in
the group that had greater variability between species. Thus, the
data point to the importance of biomonitoring humans for exposure
assessment rather than relying upon measurements performed in
other species.
High-resolution metabolomics can be used in multiple ways
to study the human exposome. These can be considered in lin-
ear cause-effect relationships, such as (1) linking environmental
exposure data to respective plasma levels of a chemical or its
metabolite, (2) linking plasma levels of an environmental chem-
ical to associated metabolite levels and pathway effects, (3) linking
dose-response effects in model systems with human dose response
relationships, (4) integrating exposure associated metabolic effects
with disease phenotypic markers and (5) using an integrated omics
approach to identify central pathophysiologic responses. Ongoing
collaborative studies applying high-resolution metabolomics anal-
yses to complement independently measured trichloroethylene
exposure levels, polycyclic aromatic hydrocarbon concentrations,
polyﬂuorinated hydrocarbon levels and cadmium body burden,
show that these approaches are sound and broadly useful. Some
examples are given below with comments on limitations and
D.P. Jones / Toxicology Reports 3 (2016) 29–45 39
Fig. 4. Data characteristics for high-resolution metabolomics. A. xMSanalyzer provides a summary of data characteristics including histograms showing the distribution of
the  log of ion intensity, the distribution of the median coefﬁcient of variation for metabolites and the distribution of the percentage of missing values for the metabolites. B. A
type  1 Manhattan plot is the negative log p as a function of m/z for a statistical analysis of each metabolite. This illustration is from a study to evaluate metabolites correlated
with  an amino acid. In the plot, ions with non-signiﬁcant raw p are green, those positively associated are in red and those negatively associated are in blue. The broken
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etention time. This plot is useful for separations obtained with C18 chromatograph
he  retention time provides useful information concerning the properties of the che
pportunities for development. In consideration of such data, one
ust remain vigilant to protect against interpretation of associa-
ions in metabolomics data as proof of causal relationships.
.1. Metabolome-wide association study (MWAS) for
nvironmental associations of disease
In a pilot study of neovascular age-related macular degener-
tion (NVAMD), we performed an MWAS  of 26 patients and 19
ontrols and found 94 m/z  features associated with NVAMD after
alse discovery rate correction at 0.05 (Fig 6A) [32]. Some unan-
icipated pathway associations were present, such as bile acid
etabolism, but an observation of interest for possible environ-
ental cause of disease was a feature with m/z 308.857, which
ad a high-resolution match to the K+ adduct of beta-2,3,4,5,6-
entachlorocyclohexanol. Although there were no other matches
n the database for this ion, a single match without conﬁrmed
dentity may  not be considered worthy of closer examination.
n correlation analyses, however, this ion correlated with m/z
53.103, and both of these correlating ions also correlated with m/z
76.845. The latter ion had raw p < 0.05 for association with NVAMD
nd was excluded after FDR correction. m/z  376.845 matched the
a+ adduct of 7-hydroxy-1,2,3,6,8-pentachlorodibenzofuran and
,2,3,7,8-pentachlorodibenzodioxin. An associated 37Cl form sug-
ested correct identiﬁcation as a chlorinated chemical, but the
ample availability was too low to conﬁrm identity for either. line). C. A type 2 Manhattan plot is the same data as in B plotted as a function of
ause more hydrophobic lipid-like chemicals elute at greater retention times. Thus,
.
Importantly, the results show that FDR protects against type 1 sta-
tistical error (false inclusion of incorrect chemicals), but does so by
ignoring type 2 statistical error (exclusion of correct chemicals).
The results showing one of two highly correlated pentachlori-
nated chemicals was excluded because of FDR ﬁltering illustrates
a weakness in use of FDR correction as being overly stringent for
discovery-based research. A limitation in this discovery approach
is that associations only provide circumstantial evidence that pen-
tachlorochemicals could contribute to NVAMD. On the other hand,
they illustrate the importance of interpreting data collectively. In
this case, two  ions matching pentachlorinated hydrocarbons were
associated with NVAMD and indicated that follow-up is needed to
determine whether these low-level environmental chemicals could
be causally related to disease.
5.2. MWAS to discover co-exposures and possible underlying
mechanisms
Demonstration of ability to detect co-exposures is provided by
analysis of cotinine in 30 samples without information concern-
ing smoking history. Partial least squares-discriminant analysis
(PLS-DA) showed clear separation where the samples were clas-
siﬁed as smokers and non-smokers based upon plasma cotinine
levels (Fig 6B). MWAS  of cotinine (Fig 6C) showed m/z  features
associated with cotinine; these included expected metabolites,
hydroxycotinine (m/z 193.0966) and norcotinine (m/z 163.0863). In
40 D.P. Jones / Toxicology Reports 3 (2016) 29–45
Fig. 5. High-resolution metabolomics workﬂow. A. An MWAS  was performed for pulmonary tuberculosis (TB) patients compared to uninfected household controls. Respective
broken lines, from bottom, raw p = 0.05, FDR = 0.2, FDR = 0.05. B. Selected metabolites that differ in A are plotted using box and whiskers plots. C. Two-way hierarchical cluster
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ddition, positive correlation was obtained with methoxypyrazine
m/z 111.0555), a ﬂavoring additive for cigarettes. Network asso-
iations (Fig 6D) performed by MetabNet [41] and metabolic
athway analysis revealed signiﬁcant associations with methio-
ine metabolism, with a negative association of cotinine with
-methylmethionine (m/z 208.0399). Although little studied, S-
ethylmethionine is a product of a mitochondrial enzyme that
ses S-adenosylmethionine to methylate methionine; the func-
ion of S-methylmethionine is unknown. The results show that
igh-resolution metabolomics provides a platform for discovery
f co-exposures and also to detect unanticipated association with
ltered methionine metabolism.
.3. Use of translational models to discover exposure-associated
etabolic effects
In a study of atrazine in mice, we found that short-term atrazine
xposure (125 mg/kg) in male C57BL/6 mice disrupted tyrosine,
ryptophan, linoleic acid, and -linolenic acid metabolism [23].
n unpublished studies, two of the metabolites of atrazine found
n mice, deisopropylatrazine (DIP; m/z 174.0536) and deethyla-
razine (m/z 188.0700), had high-resolution matches in samples
rom healthy humans (m/z 174.0540 and m/z  188.0697, respec- and that the metabolites are associated into clusters. D. Use  of Kyoto Encyclopedia
ve a depiction of the types of chemicals that differ between patients and controls.
tively). The latter identiﬁcation is ambiguous, however, because
a tryptophan metabolite, indoleacrylic acid, also matches this m/z
and has an overlapping retention time. The feature matching DIP
had a signiﬁcant but weak (r = 0.26) correlation with an ion match-
ing hydroxyatrazine (m/z 220.1773) and both features correlated
with Phe and other indole-containing metabolites. The data show
that results from dose-response ﬁndings in model systems can
be used to search HRM repositories of human metabolomics data
to test for correlations of environmental chemicals and biologic
effects. This use of established cause-effect relationships from ani-
mal  models to test for the same associations in human populations
can provide a cost-effective approach to improve understanding of
relevant exposures in the general population. The data also show
that caution will be required to avoid misinterpretation due to iso-
baric chemicals, which cannot be distinguished without further
analysis.
5.4. Use in health prediction with case-control designIn a high-resolution metabolomics study of Parkinson Disease
progression [38], signiﬁcant differences between 80 patients and 20
controls included matches to a polybromodiphenyl ether (PBDE),
tetrabromobisphenol A, octachlorostyrene and pentachloroethane.
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Fig. 6. High-resolution metabolomics provides an approach to detect environmental chemicals associated with disease and to discover co-exposures of chemicals. A. MWAS
of  age-related macular degeneration (AMD) patients and controls revealed associations of chemicals matching pentachlorochemicals with AMD [32]. B. PLS-DA of smokers
and  non-smokers, classiﬁed by plasma cotinine concentrations, showed complete separation. C. MWAS  of the data in B showed that 7 metabolites were correlated with
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y  DI Walker and bioinformatics analyses performed by Karan Uppal.
erum samples were from a case-control study that enrolled PD
atients and population-based controls between 2001 and 2007
n Central California and followed cases until 2011, death or loss
o follow-up [4]. Groups of subjects (80 from 146 PD and 20 from
ontrols) were matched as best possible by age (+/− 5years), gen-
er (male, female), smoking status (never, former, current) and
mbient pesticide exposure. The m/z matching PBDE had a mean
ntensity 50% above controls. m/z 282.046, matching 2-amino-
,2-bis(p-chlorophenyl) ethanol, was more than 50% higher in
ndividuals with rapid disease progression. Although these pop-
lation sizes are too small to make ﬁrm conclusions, the results
ndicate that high-resolution environmental metabolomics has the
otential to provide a broadly applicable tool to screen for possible
nvironmental contributions to disease and disease progression.
.5. Integrated omics to support mechanistic understanding
HRM is powerful as a stand-alone platform but becomes much
ore powerful when used in combination with other omics
pproaches. A transcriptome–metabolome wide association study
TMWAS) was  used to investigate complex cellular responses to a
ombination of a fungicide, maneb (MB), and an herbicide, paraquat
PQ) [10]. The combination of MB  + PQ had been linked in epi-ine. D. Network analyses using MetabNet [41] showed that cotinine was associated
hylmethionine. B–D are unpublished data from mass spectral analyses performed
demiologic studies as a potential environmental cause of Parkinson
Disease [37,43]. Using different concentrations and measuring gene
expression changes and metabolomics under conditions without
cell death, interactions of gene expression and metabolism were
evaluated (Fig 7A). The results showed that four central clusters of
gene-metabolite associations were present (Fig 7B), with one clus-
ter representing a hub apparently linked to toxicity and consisting
of an apoptosis gene and genes for two cation transporters and asso-
ciated regulatory protein. Other clusters included two hubs of genes
for adaptive systems and a ﬁnal cluster representing a hub of stress
response genes. The results show that central mechanistic hubs can
be identiﬁed in terms of the strength of correlations of genes and
metabolites under conditions of a toxicological challenge.
A second example of integrated omics involves use of redox
proteomics in combination with HRM to study mechanisms of
cadmium (Cd) toxicity. Cd is not redox active yet is known to pref-
erentially cause oxidation of mitochondrial proteins. Mice were
dosed with Cd and isolated liver mitochondria were analyzed for
protein oxidation using MS-based redox proteomics [9]. The results
showed that the most central mitochondrial pathways with pro-
teins undergoing oxidation were those involved in -oxidation
of fatty acids and branched chain amino acid metabolism. HRM
showed that the central mitochondrial pathways with metabo-
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Fig. 7. Integration of high-resolution metabolomics with gene expression and redox proteomics analyses. A. A heatmap of associations of top correlations between tran-
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ites responding most to Cd were acylcarnitines and branched
hain amino acid metabolites (Fig 7C). An additional example is
rovided for integration of the microbiome and metabolome [5].
lthough there are currently only a limited number of studies in
hich metabolomics is combined with other omics approaches in
nvironmental research, the results available show that this is a
owerful approach which can be used in cell culture and in vivo to
tudy environmental mechanisms of disease.
. Universal exposure surveillance: an interim solution for
xposome research
Chemical space is inﬁnite, and the sequence and diversity of
ossible human exposures is inﬁnite. Yet within these realms of
nﬁnity, the earth is ﬁnite, human lifespan is ﬁnite and a human
xposome is ﬁnite. In the face of inﬁnite possibilities, the challenge
s not to partition inﬁnity but rather to develop realistic and achiev-
ble goals for human exposures within the time frame of human
ifespan.
Humans can live over 100 years so sequencing an individual’s
ifelong exposures is a long-term project. Multiple options are avail-
ble to move this forward, such as analysis of archival samples that
ave been collected over decades for some cohorts and longevity
tudies in relatively short-lived species, like domestic dogs or non-ngicide, maneb, and the herbicide, paraquat. B. Network associations showed four
 pathways in which mitochondrial proteins were oxidized in response to cadmium.
human primates. These approaches are useful to gain information
on internal doses of environmental chemicals but do not effectively
capture external environmental chemical burden. Thus, a better
scientiﬁc foundation may  be obtained through development of a
universal exposure surveillance system. In this context, “universal”
does not mean “comprehensive”, but rather means a standardized
way to routinely capture and assemble information on the range
and prevalence of chemicals across geographies and biologic sys-
tems.
A practical initiative would be to establish a universal expo-
sure surveillance program with two  speciﬁc goals: (1) to provide a
periodic census of detectable chemicals within speciﬁc geographies
and (2) to provide a periodic census of detectable chemicals within
humans. Such a program need not be daunting. A broad spectrum
of analytical tools is available, geographic regions and populations
are extensively mapped, and effective organizational structures are
in place to establish priorities according to available resources.
Routine air and water surveillance methods are already in place
so that minimal additional costs would be needed for acquisition
for samples of these environmental media. Sampling of soil and
built environments will require more strategic planning, but also
can build upon existing surveillance methods. A key difference in
analytical strategies, however, is that instead of targeted analyses of
a small number of chemicals of concern, effective analytical tools
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re needed to broadly survey chemical space. Development of a
eographic grid system for regular interval measurements of chem-
cals would allow generation of maps that would reveal changes in
he chemical environment, analogous to the maps of temperature,
ainfall, particulate levels, and other commonly available environ-
ental metrics.
In this regard, the healthcare system provides an already estab-
ished system that could be used with HRM to obtain regular
ensus of the human body burden of environmental chemicals.
s described above, HRM is well developed for use as a general
urveillance tool. High-resolution mass spectrometers are widely
vailable and have been applied to study a spectrum of disease
tates and physiologic conditions. These include studies of car-
iovascular disease, obesity, diabetes, neurodegenerative disease,
ung disease, renal disease, liver disease, eye disease, infections
nd immunity and aging. The important conclusion is that high-
esolution FTMS and Q-TOF methodologies are robust, affordable
nd widely available.
An immediate interim solution to sequencing the exposome
ould be to use this technology to support a periodic census of
etectable chemicals within humans. Within the healthcare sys-
em, this could be done with minimal collection costs. Discarded
lood from many collection purposes could be used. For instance,
e-identiﬁed samples collected from mandatory drug screenings or
IV testing could be used; prenatal or newborn disease screening
amples could be used; samples for toxicology testing in emer-
ency rooms could be used. With appropriate incentives to replace
urrent blood chemistry analyses with high-resolution technology,
nvironmental biomonitoring could be obtained as a byproduct of
any clinical analyses with minimal increase in cost.
Such measures would necessarily be limited by current state-of-
he-art in exposure science and biomonitoring research. But the key
ractical issue is that before a cumulative measure of environmen-
al inﬂuences and biological responses throughout the lifespan can
e achieved, a rigorously standardized system is needed to mea-
ure environmental inﬂuences and biologic responses. The HRM
latform provides such a tool and therefore could be useful for
nitiation of a universal exposure surveillance system.
. A framework to sequence the human exposome
A universal exposure surveillance system using HRM as a core
lement could provide short-term beneﬁts as a resource for pre-
ictive modeling of human exposures and health trends. The
ong-term beneﬁts are greater, however, in that the structure
rovides a core upon which a program to sequence the human
xposome becomes practical. Central arguments can be summa-
ized as follows:
.1. Use plasma as a common reference
Blood plasma is commonly available during routine health
xamination and provides a logical place to start with creation of
n exposome-sequencing project. Plasma is a ﬂuid that is central
n physiology and supports nutrient supply, elimination of wastes
nd hormonal communication in homeostatic regulation. Urine
rovides a suitable alternative, especially for children, but has a
isadvantage in not providing plasma metabolic data to monitor
iologic effects of exposures.
.2. Use HRM upon plasma collection to obtain advanced blood
hemistry analysisAn advantage of HRM is that a very broad spectrum of chemicals
s detected, including many environmental chemicals and repre-
entative chemicals from most metabolic pathways. Chemicals areorts 3 (2016) 29–45 43
detected that are derived from environmental and other exposures,
including diet, microbiome, supplements and drugs. Metabolites in
plasma provide an integrated measure of the biologic response of an
individual to exposures, including behavioral factors such as exer-
cise and emotional stress. Comparison of data to reference plasma
for normal populations shows how an individual differs from a pop-
ulation. The potential utility of such comparisons is enhanced by
the recent demonstration that HRM can be used to quantify chemi-
cals over more than seven orders of magnitude absolute abundance
[11]. Furthermore, this blood chemistry proﬁle provides metabolite
measurements of an individual within the context of ongoing expo-
sures and disease processes so that longitudinal analyses can be
used to evaluate lifelong changes in exposure and metabolism. This
translates the concept of time-point measurements into a cumula-
tive lifelong measurement as implied by the term “sequencing the
exposome”.
7.3. Use advanced data extraction algorithms to maximize
information capture
Advanced analytical methods are available to systematically
measure thousands of chemicals in plasma. As outlined above,
these can be queried for associations with disease and, for uniden-
tiﬁed chemicals, can be retrospectively studied for identiﬁcation.
While uncertainties exist concerning the best platform for cost, cov-
erage and quantitative reproducibility, arguments are sufﬁciently
sound to choose a simple protein removal step and a combination
of ionization and chromatography methods, with at least triplicate
analyses.
7.4. Deliver useful clinical measures as part of health records
HRM provides more information than provided by contempo-
rary blood chemistry measurements. The data can be provided in
a quantitative form that is meaningful for evaluation of nutrition,
metabolism and disease. This information can be useful for health
management and could be developed for this purpose and pro-
vided back to the individual for personal study and reference. In
this regard, it is important to note that chemicals of abuse will also
be measured. Consequently, procedures will be needed to ensure
privacy and protect individual liberties. Most importantly, as indi-
cated above, collection of uniform exposure surveillance data for
an individual over time provides a lifecycle framework for study of
the exposome.
7.5. Preserve raw data and extracted data in accessible,
cumulative repositories
Databases of chemical information are less expensive to main-
tain and more stable against decay than stored blood samples.
Thus, ongoing analysis of samples with a cumulative data struc-
ture should be established. An accessible central repository of
data would enable generalized integration of multiple exposure
metrics by providing a central reference. For instance, the data
include measures of commonly used blood chemistry measures,
such as glucose, bilirubin, creatinine, urea, amino acids, vitamins
and coenzymes, steroids, free fatty acids, acylcarnitines, phos-
phatidylcholines, etc. Thus, interactions of any measured external
exposure could be evaluated against a common reference. This
could be useful to monitor changes in response to new food prod-
ucts, health policies or disease trends.
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.6. Maintain data reconciliation center independent of
epositories
Data reconciliation efforts will be needed to determine compa-
ability of data between facilities and over time. The contribution
f geography to the plasma metabolome is currently unknown,
o efforts will be needed to distinguish analytical differences and
xposure differences. Although it may  seem necessary to have
his in place prior to initiation of a universal surveillance system,
mprovements based upon quality control and on-going evaluation
ill be needed regardless. Thus, concern about quality provides no
alid excuse for delay, only a reason to invest in quality control
nd improvement as part of an exposome strategy. The methods
re good enough to initiate a program; certainly, experience will
rovide improvements.
. A call to action
Sequencing the ﬁrst human genome was a lengthy process
nd expensive, yet today analysis is routine and affordable for
any purposes. Sequencing the human exposome will also be a
engthy process and expensive. However, this can be initiated with
 practical framework using existing technologies, providing future
enerations the information necessary to use this to improve indi-
idual health and also protect against insidious accumulation of
ow abundance chemicals that can adversely affect humans and
cologic systems.
Christopher Wild recognized the inherent weaknesses in epi-
emiologic approaches and genomics to deliver real understanding
o the causes of most chronic disease [44]. The exposome is a neces-
ary complement to the genome to understand causes and improve
revention of human disease. The genome has been sequenced. The
pportunity lies before us to sequence the exposome. The time has
rrived to seize that opportunity.
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